Jian Li
Peking University
7 Papers
33 Citations
Jian Li is an academic researcher from Peking University. The author has contributed to research in topics: Survival rate & Medicine. The author has an hindex of 6, co-authored 7 publications.
Chat about Author
Papers
The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer.
Zhi Peng,Siyuan Cheng,Yan Kou,Ziqi Wang,Rong Jin,Han Hu,Xiaotian Zhang,Jifang Gong,Jian Li,Ming Lu,Xicheng Wang,Jun Zhou,Zhihao Lu,Quan Zhang,David T.W. Tzeng,Dongtao Bi,Yan Tan,Lin Shen +17 more
TL;DR: The impact of gut microbiomes on anti–PD-1/PD-L1 outcomes is highlighted, at least in a subset of patients with GI cancer, and the potential of the microbiome as a marker for immune-checkpoint blockade responses is suggested.
Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial.
Ming Lu,Panpan Zhang,Yanqiao Zhang,Zhongwu Li,Jifang Gong,Jie Li,Jian Li,Yan Li,Xiaotian Zhang,Zhihao Lu,Xicheng Wang,Jun Zhou,Zhi Peng,Weifeng Wang,Hui Feng,Hai Wu,Sheng Yao,Lin Shen +17 more
TL;DR: Toripalimab had antitumor activity and safety in treating recurrent or metastatic NENs and patients with positive PD-L1 expression, TMB-H (top 10%), and/or microsatellite instable (MSI-H) might preferentially benefit from the treatment.
Phase II Study of Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Perihilar Cholangiocarcinoma.
Xiaodong Wang,Jungang Hu,Guang Cao,Xu Zhu,Yong Cui,Xinqiang Ji,Xuan Li,Renjie Yang,Hui Chen,Hai-Feng Xu,Peng Liu,Jian Li,Jie Li,Chunyi Hao,Baocai Xing,Lin Shen +15 more
TL;DR: HAI with oxaliplatin and 5-fluorouracil may be an encouraging treatment choice for advanced PCC due to its high tumor control, survival benefit, and low toxicity, especially in patients with periductal infiltrating pattern.
54
Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate: Apparent Diffusion Coefficient in the Evaluation of Therapy Response in Patients
TL;DR: Comparatively low pretherapy ADC and marked ADC increase at 1 week after therapy is associated with good response to imatinib mesylate in patients with GISTs.
54
Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first‐line chemotherapy
Furong Kou,Zhihao Lu,Jian Li,Xiaotian Zhang,Ming Lu,Jun Zhou,Xicheng Wang,Jifang Gong,Jing Gao,Jie Li,Yan Li,Lin Shen +11 more
TL;DR: It is shown that pretreatment lymphopenia is a good prognostic factor as well as a predictive factor for tumor response and chemotherapy‐related hematological toxicity in metastatic ESCC.
33